program overview
Program Description
The American Diabetes Association Standards for Medical Care in Diabetes—2020 provide the strongest recommendations to date for the early use of glucagon-like peptide (GLP)-1 receptor agonists (RAs) or sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2DM) who are at high risk for, or have already-established cardiovascular (CV) disease, heart failure, or chronic kidney disease. Notably, these guidelines recommend the early use of these agents in appropriate patients regardless of current or target A1C. In this activity, participants are challenged to make appropriate, evidence-based clinical decisions for a patient who presents with T2DM and a history of CV disease.
Format
Interactive Video Case Study
Learning Objectives
After completing this activity, participants should be better able to:
- Apply current guidelines and evidence supporting early initiation of GLP-1 RAs in appropriate patients with T2DM
- Outline the role of GLP-1 RA therapy in patients requiring improved glycemic control, weight reduction, and/or CV risk reduction
- Implement strategies that incorporate shared decision-making with patients to foster adherence and improve patient outcomes
Target Audience
NPs and PAs


Details
Joint Accreditation Statement
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until March 30, 2021. PAs should only claim credit commensurate with the extent of their participation.
PA planner: Lawrence Herman, MPA, PA-C, University of South Carolina School of Medicine, Columbia, South Carolina
This activity was developed from a series of programs co-supported by educational grants from AbbVie Inc.; Eisai; Genentech; GlaxoSmithKline; Novo Nordisk Inc.; Sanofi Genzyme and Regeneron Pharmaceuticals; and Sunovion Pharmaceuticals Inc.
This activity is supported by an educational grant from Novo Nordisk Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Kruger: consultant/speakers bureau: Abbott, Dexcom, Lexicon, Lilly, Novo Nordisk, Sanofi.
Mr Herman: consultant/speaker: Novo Nordisk.
None of the members of the Planning Committee or CE Alliance staff have any relevant relationships to disclose, except Ms Kruger and Mr Herman as noted above.
Participants wishing to earn CE/CME credit must:
- Review the content
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hour.
Release date: March 31, 2020
Expiration date: March 30, 2021
Any internet connected computer or mobile device with any of the following browsers: Internet Explorer, Google Chrome, Mozilla Firefox, Safari.
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 95319CPCE-7C